Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
07 August 2023 - 10:05PM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
announced the appointment of Christopher J. Silber, M.D. as Chief
Medical Officer. Dr. Silber brings over 30 years of
biopharmaceutical industry experience and a track record of
clinical and regulatory success developing novel therapeutics in
neuroscience.
“We are thrilled to welcome Dr. Silber to Vigil
as our new Chief Medical Officer at this pivotal time as we advance
VGL101 through Phase 2 clinical development and work towards moving
our small molecule program into the clinic later this year,” said
Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief
Executive Officer of Vigil. “His proven clinical leadership and
extensive neuroscience and rare disease drug development experience
will be instrumental to our patient-centered mission of developing
potentially transformative treatments for rare and common
neurodegenerative diseases.”
Dr. Silber joins Vigil from Nocion Therapeutics,
where he was Chief Medical Officer and led the clinical strategy
for the company’s small molecule platform, including development of
NTX-1175, a new chemical entity for cough indications. Prior to
Nocion, he served as Senior Vice President, Clinical Development at
Sage Therapeutics, where he led clinical development efforts for
the portfolio, supporting the U.S. Food and Drug Administration
(FDA) approval of ZULRESSO® for the treatment of postpartum
depression, zuranolone development for major depressive disorder
and postpartum depression, and progression of the early neurology
therapeutics pipeline. Previously at Agilis Biotherapeutics, Dr.
Silber served as Chief Medical Officer where he oversaw the gene
therapy pipeline focused on rare diseases of the CNS, including
work contributing to the subsequent approval of Upstaza™ for
aromatic L-amino acid decarboxylase (AADC) deficiency. He also held
positions of increasing responsibilities at Lundbeck, Takeda,
Hospira and Abbott Laboratories. Dr. Silber earned his B.A. in
Psychology from Tufts University and his M.D. at Jacobs School of
Medicine and Biomedical Sciences at the University of
Buffalo.
“Vigil’s precision-based development approach
targeting microglia represents a new frontier in the treatment of
neurodegenerative diseases, which remains an area of high unmet
medical need,” said Dr. Silber. “I look forward to applying my
experience in clinical development and neuroscience to accelerate
the development of the Company’s pipeline assets and support our
mission to bring novel therapies to people living with these
devastating diseases.”
About Vigil
Neuroscience Vigil Neuroscience is a clinical-stage
biotechnology company focused on developing treatments for both
rare and common neurodegenerative diseases by restoring the
vigilance of microglia, the sentinel immune cells of the brain. We
are utilizing the tools of modern neuroscience drug development
across multiple therapeutic modalities in our efforts to develop
precision-based therapies to improve the lives of patients and
their families. VGL101, our lead clinical candidate, is a fully
human monoclonal antibody agonist targeting human triggering
receptor expressed on myeloid cells 2 (TREM2) in people with
adult-onset leukoencephalopathy with axonal spheroids and pigmented
glia (ALSP), a rare and fatal neurodegenerative disease. We are
also developing a novel small molecule TREM2 agonist program to
treat common neurodegenerative diseases associated with microglial
dysfunction, with an initial focus on Alzheimer’s disease (AD) in
genetically defined subpopulations.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements” of Vigil Neuroscience’s
(“Vigil” or the “Company”) that are made pursuant to the safe
harbor provisions of the federal securities laws, including,
without limitation, express or implied statements regarding: the
Company’s strategy, business plans and focus; the developmental,
regulatory and clinical progress and timing of the preclinical and
clinical development of Vigil’s programs and the expected
therapeutic benefits of such programs; expectations regarding the
development of VGL101 in ALSP and other indications; expectations
regarding the development of its small molecule TREM2 agonist
program in Alzheimer’s Disease (AD); expectations regarding the
development of other pipeline candidates; the anticipated
contribution of the Company’s executives to its operations and
progress. Factors that could cause actual results to differ
include, but are not limited to, risks and uncertainties related to
uncertainties inherent in the identification and development of
product candidates, including the conduct of research activities
and the initiation and completion of preclinical studies and
clinical trials; uncertainties as to the availability and timing of
results and data from preclinical and clinical studies; the timing
of the Company’s ability to submit and obtain regulatory clearance
for investigational new drug applications and initiate additional
clinical trials; whether results from preclinical studies will be
predictive of the results of later preclinical studies and clinical
trials; the Company’s ability to initiate and complete its current
and expected clinical trials; whether Vigil’s cash resources will
be sufficient to fund its foreseeable and unforeseeable operating
expenses and capital expenditure requirements as well as the risks
and uncertainties identified in the Company’s filings with the
Securities and Exchange Commission (SEC), including Vigil’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2023
and in any subsequent filings it may make with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Vigil undertakes no duty to update such
information except as required under applicable law. Readers should
not rely upon the information on this page as current or accurate
after its publication date.
Investor Contact:Leah
GibsonVice President, Investor Relations & Corporate
CommunicationsVigil Neuroscience, Inc.lgibson@vigilneuro.com
Media Contact:Megan
McGrathMacDougall Advisorsmmcgrath@macdougall.bio
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024